阿尼鲁单抗治疗活动性系统性红斑狼疮的3期TULIP试验中狼疮低疾病活动状态的达标情况
该研究事后分析汇总TULIP-1和TULIP-2两项3期试验数据,评估接受标准治疗的中重度系统性红斑狼疮(SLE)患者中阿尼鲁单抗治疗与狼疮低疾病活动状态(LLDAS)达标的关系。第52周时阿尼鲁单抗组30.0%患者处于LLDAS,安慰剂组为19.6%(OR 1.8,95%CI 1.3至2.5,p=0.0011),且阿尼鲁单抗与更早、更持久和更持续的LLDAS达标相关。
要点
- 第52周阿尼鲁单抗组30.0%达到LLDAS,安慰剂组19.6%(OR 1.8,p=0.0011)。
- 阿尼鲁单抗组首次LLDAS达标更早(HR 1.76,95%CI 1.35至2.30,p<0.0001)。
- LLDAS达标与BICLA和SRI(4)应答高度相关但更严格。
核心结论
- LLDAS达标与BICLA和SRI(4)应答高度相关,但LLDAS比BICLA和SRI(4)应答更严格。
- 与安慰剂相比,阿尼鲁单抗治疗与更早、更频繁、更持久且更持续的LLDAS达标相关。
研究设计与样本
- 对TULIP-1(NCT02446912)和TULIP-2(NCT02446899)两项阿尼鲁单抗3期试验数据进行的汇总事后分析。
- 纳入接受标准治疗的中重度SLE患者,共819例。
- LLDAS定义为SLE疾病活动指数2000≤4且无主要器官活动、无新发疾病活动、医生整体评估≤1、泼尼松≤7.5 mg/天且无非标准免疫抑制剂给药。
主要发现
- 不考虑治疗分组,205/819(25.0%)患者在52周时达到LLDAS,其中186/205(90.7%)同时也是BICLA应答者。
- 52周BICLA应答者中186/318(58.5%)达到LLDAS,SRI(4)应答者中203/380(53.4%)达到LLDAS。
- 52周时LLDAS达标者患者整体评估评分较基线的改善是未达标者的三倍。
- 52周时阿尼鲁单抗组30.0%患者处于LLDAS,安慰剂组为19.6%(OR 1.8,95%CI 1.3至2.5,p=0.0011)。
- 与安慰剂相比,阿尼鲁单抗治疗与首次LLDAS达标更早(HR 1.76,95%CI 1.35至2.30,p<0.0001)、LLDAS累积时间增加(p<0.0001)及持续LLDAS可能性更高(p<0.001)相关。
关键数值与推荐
- LLDAS定义:SLE疾病活动指数2000≤4且无主要器官活动、无新发疾病活动、医生整体评估≤1、泼尼松≤7.5 mg/天且无标准免疫抑制剂给药。
- 第52周LLDAS达标率:阿尼鲁单抗组30.0% vs 安慰剂组19.6%(OR 1.8,95%CI 1.3至2.5,p=0.0011)。
- 首次LLDAS达标时间:阿尼鲁单抗组较安慰剂组更早(HR 1.76,95%CI 1.35至2.30,p<0.0001)。
- 第52周SLE缓解定义缓解率:阿尼鲁单抗组15.3% vs 安慰剂组7.6%(OR 2.2,95%CI 1.4至3.6,p=0.0013)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with systemic lupus erythematosus (SLE), lupus low disease activity state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS attainment in anifrolumab-treated patients. METHODS: We performed post hoc analysis of pooled Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP-1) (NCT02446912) and TULIP-2 (NCT02446899) anifrolumab phase 3 trial data in patients with moderate to severe SLE receiving standard therapy. LLDAS was defined as: SLE Disease Activity Index 2000 ≤4 without major organ activity, no new disease activity, Physician's Global Assessment ≤1, prednisone ≤7.5 mg/day and no non-standard immunosuppressant dosing. Time to first LLDAS attainment was compared between groups using Cox regression modelling; responses were compared using logistic regression. RESULTS: Agnostic to treatment, 205/819 (25.0%) patients attained LLDAS at week 52; 186/205 (90.7%) were also British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA)-responders. Among BICLA-responders at week 52, 186/318 (58.5%) attained LLDAS; 203/380 (53.4%) SLE Responder Index-4 (SRI(4)) responders attained LLDAS. Improvements from baseline in patient global assessment scores at week 52 were threefold greater in LLDAS-attainers. At week 52, 30.0% of anifrolumab-treated patients and 19.6% of placebo were in LLDAS (OR 1.8, 95% CI 1.3 to 2.5, p=0.0011). Compared with placebo, anifrolumab treatment was associated with earlier LLDAS attainment (time to first LLDAS, HR 1.76, 95% CI 1.35 to 2.30, p<0.0001), increased cumulative time in LLDAS (p<0.0001) and higher likelihood of sustained LLDAS (p<0.001). Anifrolumab treatment was also associated with higher rates of Definition of Remission in SLE remission at week 52 (15.3% vs 7.6%; OR 2.2, 95% CI 1.4 to 3.6, p=0.0013). CONCLUSIONS: LLDAS attainment was highly associated with, but more stringent than, BICLA and SRI(4) responses. Compared with placebo, anifrolumab treatment was associated with earlier, more frequent, and more prolonged and sustained LLDAS. TRIAL REGISTRATION NUMBERS: NCT02446912 and NCT02446899.
引用
- Morand EF, Abreu G, Furie RA, et al. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis. 2023. PMID: 36690388. doi:10.1136/ard-2022-222748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。